Skip to main content
Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
39.73
+0.58 (1.48%)
At close: Dec 5, 2025, 4:00 PM EST
39.85
+0.12 (0.30%)
After-hours: Dec 5, 2025, 7:47 PM EST

Revenue

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 2016 - 2020
Period Ending
 Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2016 - 2020
Cystic Fibrosis Franchise Revenue
819.92M826.21M
Log In
Log In
Log In
Upgrade
Evrysdi Revenue
213.41M224.43M
Log In
Log In
Log In
Upgrade
Trelegy Revenue
149.91M146.92M
Log In
Log In
Log In
Upgrade
Tremfya Revenue
149.47M147.14M
Log In
Log In
Log In
Upgrade
Tysabri Revenue
120.29M124.82M
Log In
Log In
Log In
Upgrade
Imbruvica Revenue
-131.09M
Log In
Log In
Log In
Upgrade
Xtandi Revenue
--
Log In
Log In
Log In
Upgrade
Promacta Revenue
--
Log In
Log In
Log In
Upgrade
Other Products Revenue
636.85M548.82M
Log In
Log In
Log In
Upgrade
Total Income from Financial Royalty Assets
2.23B2.15B
Log In
Log In
Log In
Upgrade
Revenue from Intangible Royalty Assets
--
Log In
Log In
Log In
Upgrade
Other Royalty Income
--
Log In
Log In
Log In
Upgrade
Other Royalty Income and Revenue
119.28M114.15M
Log In
Log In
Log In
Upgrade
Revenue (Other)
-213.41M-224.43M
Log In
Log In
Log In
Upgrade
Revenue (Total)
2.35B2.26B
Log In
Log In
Log In
Upgrade

Key Performance Indicators

Fiscal year is January - December.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022 FY 2021 2016 - 2020
Period Ending
 Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 2016 - 2020
Portfolio Receipts
3.12B2.80B
Log In
Log In
Log In
Upgrade